Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Immunotherapy Drugs Shrink Brain Metastases from Melanoma - NCI

Combination immunotherapy shrinks metastatic brain cancer

The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence

Figure 1 from Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)

Actualizaciòn en el tratamiento de metàstasis cerebrales por melanoma

Full article: Efficacy and safety of the combined use of ipilimumab and nivolumab for melanoma patients with brain metastases: a systematic review and meta-analysis

Ipilimumab Plus Nivolumab Improves Survival in Melanoma With Brain Metastases - Cancer Therapy Advisor

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Addition of nivolumab, ipilimumab to chemotherapy extends OS in NSCLC with brain metastases

Real world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastases - Moyers - 2021 - Cancer Medicine - Wiley Online Library